Ubrogepant (Ubrelvy) vs Zavegepant (Zavzpret)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Migraine
Shared mechanism: CGRP receptor · full Migraine pipeline
Ubrogepant (Ubrelvy)
Marketed by AbbVie
NCT02828020 · Phase 3 · completed
This was a large, randomized, double-blind, placebo-controlled trial with 1,672 participants. Both ubrogepant doses met both primary clinical endpoints, with statistically significant improvements over placebo in pain freedom and relief of the most bothersome migraine-associated symptom at 2 hours.
Next expected readout: May 2027 · NCT05125302 (registry estimate)
Reported efficacy
Percentage of Participants Reporting Absence of Headache of Moderate/Severe Intensity Within 24 Hours Post-dose (24 hours after taking double-blind study intervention during the prodrome): Percentage of Participants Reporting Absence of Headache of Moderate/Severe Intensity Within 24 Hours Post-dose (24 hours after taking double-blind study intervention during the prodrome): Placebo 121 Participants | Ubrogepant 100 mg 190 Participants (met)
Result source: NCT04492020
Zavegepant (Zavzpret)
Marketed by Pfizer
NCT04571060 · Phase 3 · completed
This was a large randomized, double-blind, placebo-controlled trial, with 623 zavegepant-treated and 646 placebo-treated participants included in the efficacy analysis. Both prespecified primary clinical endpoints were met: pain freedom and freedom from the most bothersome symptom at 2 hours were significantly higher with zavegepant than placebo.
Next expected readout: March 2027 · NCT06401642 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Migraine
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Zavegepant (Zavzpret): registry results are on file for Migraine, but their comparison mappings are not yet available.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ubrogepant (Ubrelvy)'s landscape · Zavegepant (Zavzpret)'s landscape